French contrast developer Guerbet has signed an agreement to promote and distribute its Lipiodol Ultra-Fluid liver contrast agent in China.
Guerbet signed the deal with pharmaceutical distributor and importer Beijing Keyuan Xinhai Pharmaceutical to distribute and commercialize Lipiodol.
Lipiodol was developed for diagnostic radiology applications, including liver lesion diagnosis, lymphography, and hysterosalpingography, and it is also used in interventional radiology as a contrast agent, a drug-eluting vehicle, and an arterioportal transient embolic, the company said.
Liver cancer is particularly prevalent in China due to the prevalence of viral hepatitis, Guerbet said.
